Vista Group Signs Enterprise Agreement with Odeon Cinemas Group – Europe’s Largest Cinema Operator
Vista Group International Ltd (NZX & ASX: VGL) is delighted to announce it has signed an agreement with Odeon Cinemas Group (‘ODEON’) to deliver solutions designed to transform guest journey engagement, influence and insight for ODEON. The combination of Vista’s cinema management software portfolio (‘Vista Cinema’), Movio Cinema big data analytics and marketing, Cinema Intelligence film forecasting and MX Film – real-time distribution of digital media assets – represents one of the most comprehensive roll-outs of Vista’s solutions ever undertaken.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190210005040/en/
ODEON, Europe’s largest cinema operator, with more than 360 cinemas located in 13 European countries, will deploy Vista across 120 cinema sites in the UK and Ireland.
The close integrations that exist between the Vista Group products have been recognised by ODEON as an opportunity to deploy a synergistic suite of software technology across their circuit. This is an approach to Vista deployments that will help ODEON meet their goals of providing an exceptional guest experience, whilst optimising their business operations via collaborative systems and homogeneity.
According to Odeon Cinemas Group CIO, Ian Chapple, “We’re delighted to have selected Vista Group as a strategic partner to assist us in transforming our guest experience at Odeon. We recognise the strength and depth of the Vista proposition and the experience that they bring will be key to helping us evolve our technology platforms and take the business to another level.”
“Beginning 2019 in collaboration with ODEON is the best Christmas present our team in EMEA could have wished for”, commented Mischa Kay, Managing Director of Vista Cinema, EMEA. “Aside from the importance of ODEON as a European powerhouse of exhibition, which adds to making our new partnership a total privilege, is the opportunity that Vista has, to excel in developing, managing and delivering cutting edge innovation through new products and services that span Vista Group companies.”
Vista Group CEO, Kimbal Riley is equally thrilled: “Our agreement with ODEON is a watershed moment for Vista Group”, he commented. “Our ability to deploy a wide-ranging integrated set of solutions for ODEON is a credit to the vision of our founders and to the capability of our teams across the business who imagine, design, develop and deploy technologies that delight our customers and enable the delight of their customers.”
The roll-out of the Vista solutions suite across ODEON UK and Ireland is expected to commence later this year.
About Vista Group
Vista Group International Ltd (Vista Group) is a public company, founded in New Zealand in the mid 1990’s and listed on both the New Zealand and Australian stock exchanges in 2014 (NZX & ASX: VGL). The Group provides software and additional technology solutions across the global film industry.
Cinema management software is provided by founding company Vista Entertainment Solutions (‘Vista Cinema’); Movio (the authority in moviegoer data analytics), Veezi (cloud-based software for the Independent Cinema Market), movieXchange (‘MX ‘ – connecting the movie industry to simplify the supply of film media for promotion and the sale of movie tickets), Maccs (film distribution software), Numero (box office reporting software for film distributors and cinemas), Cinema Intelligence (business intelligence solutions), Powster (creative studio and marketing platform for movie studios) and Flicks (moviegoer ‘go to’ portal for movie information), provide an innovative range of complementary products across additional film industry sectors, from production and distribution, to cinema exhibition through to the moviegoer experience.
Vista Group has offices located in New Zealand (Auckland HQ), Sydney, Cape Town, London, the Netherlands, Romania, Shanghai, Beijing, Los Angeles, and Mexico City.
About Odeon Cinemas Group
Odeon Cinemas Group is Europe's largest cinema operator, with leading positions and brands in the UK and Ireland, Spain, Italy, Sweden, Finland, Estonia, Latvia and Lithuania; and a strong presence in Norway, Germany and Portugal.
Odeon Cinemas Group is an AMC company; AMC is the largest movie exhibition company in the U.S., in Europe and throughout the world with more than 1,000 theatres and nearly 11,000 screens across the globe.
In Europe, Odeon Cinemas Group welcomes over 100 million guests each year to enjoy great hospitality while watching the latest films and entertainment in more than 360 cinemas and 2,900 screens. The Group is proud to be at the forefront of innovation by investing in fully reclining seats and offering a wide selection of food and beverage choices to create the ultimate guest experience.
For more information visit www.odeoncinemasgroup.com.
For Vista Group International/USA
Maggie Begley Communications, Los Angeles
Tel: +1 310 390.0101
For Vista Group International/UK
Branch Road, London
Tel: +44 (0) 203 189 1399
For Odeon Cinemas Group
Group Head of Communications, Odeon Cinemas Group
Tel: +44 (0) 20 7766 1809
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX®▼ (daratumumab)19.7.2019 09:59:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the skin) use of DARZALEX® (daratumumab) for the treatment of patients with multiple myeloma. This subcutaneous formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme's ENHANZE® drug delivery technology]. Daratumumab is currently only approved for intravenous (IV) use. “This new formulation is an example of our unwavering commitment to pursue innovative treatment options to support people living with multiple myeloma,” said Dr Patrick Laroche, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. “Importantly, subcutaneous daratumumab demonstrated comparable efficacy with the existing IV formulation, reduced the rate of infusion-related reactions and significantly shortened the time it takes for patients to receive treatment, fr